Provisional Agenda
(subject to change)
All times mentioned refer to British Standard Time (BST).
World Time Converter: https://www.worldtimebuddy.com
Presentation language: English
Tuesday 31st March 2021
1055: Welcome and housekeeping
Chair: Dr Koen Raemdonck
1100: Professor Achim Aigner, Professor, Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Selbst Abteilung Klinische Pharmakologie, Leipzig, Germany
Chemically improved, PEI-based polymer systems for RNA therapeutics: siRNA/miRNA delivery and beyond
1130: Dr Pavlina Konstatinova, Chief Scientific Officer, VectorY Therapeutics, Amsterdam, The Netherlands
Shifting the paradigm of gene therapy for neuromuscular diseases
1200: Professor Stephen Hart, Professor in Molecular Genetics & Deputy Head of Department, Genetics and Genomic Medicine Department, UCL Great Ormond Street Institute of Child Health, London, UK
siRNA silencing of ENaC as a therapeutic strategy for cystic fibrosis
1230: Dr Beatrice Tolksdorf, Postdoctoral Scientist, Institute of Biotechnology, Technical University of Berlin, Berlin, Germany
RNA interference against SARS-CoV2
1300: Break
Chair: Professor Stephen Hart
1320: Professor Leonidas Phylactou, Chief Executive Medical Director, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
The role of exosomal muscle-specific miRNAs
1350: Dr Ariadna Bargiela, Postdoctoral Scientist, Artero’s Lab of Translational Genomics, Department of Genetics, Faculty of Biology, University of Valencia, Valencia, Spain
Effects of miR-7 modulation on muscle atrophy-related phenotypes in myotonic dystrophy
1420: Dr Koen Raemdonck, Assistant Professor, Department of Pharmaceutics, University of Ghent Research Group on Nanomedicines, Ghent, Belgium
Repurposing of cationic amphiphiles to promote cytosolic delivery of small non-coding RNAs
1450: Dr David Evans, Chief Scientific Officer, Sirnaomics, Inc, Cambridge, MA, USA
Novel siRNA constructs containing Gemcitabine to treat cancer
1520: Professor Zdravka Medarova, Associate Professor of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
Harnessing RNAi for the treatment of cancer
1550: Professor Louise Robertson, Biomedical Sciences Research Institute, University of Ulster, Coleraine, UK
Developing mutant allele-specific gene therapies for treatment of corneal dystrophy
1620: Discussion and close of meeting
